EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck

Claudia Mercader iD, Mercedes Ingelmo-Torres, Fiorella L Roldán, Marcel Figueras, Eric Villalba, Pilar Galve, Ignacio Asiaín, Meritxell Costa, Antoni Vilaseca, Josep Oriola, Agustín Franco, Antonio Alcaraz und 1 weitere

Cancer Cytopathology · 2026-10 · 134 (10)

DOI: 10.1002/cncy.70141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 08.09.2026. Verfasst von Claudia Mercader und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratori i Servei d'Urologia, Hospital Clínic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cytodiagnosis, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nucleix and private grants awarded to LM and AA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate Bladder EpiCheck (BE) performance in detecting urothelial carcinoma (UC) and HG (high‐grade) events in patients with indeterminate cytology and negative cystoscopy.

Methods

This prospective study included 63 patients who presented with indeterminate urinary cytology and negative cystoscopy between October 2022 and April 2024. A repeated urine sample was obtained and analyzed via both urinary cytology and BE test. Patients were followed for 1 year. The diagnostic performance of each test was assessed. Logistic regression models were developed to estimate the risk of UC and HG events on the basis of repeated cytology and BE results.

Results

Thirty‐two patients (51%) experienced a UC event, of which 25 (78%) were HG events. Sensitivity (SN) for detecting UC events was significantly higher (80% vs. 17%; p < .001) for BE compared to repeated urinary cytology, whereas repeated cytology demonstrated higher specificity (SP) (59% vs. 96%; p = .02). Similar SN differences were observed for HG disease (80% vs. 25%; p < .001). However, when suspicious for high‐grade urothelial carcinoma was considered a positive cytology result, no statistically significant differences were observed between BE and repeated cytology in either SN or SP. A prognostic model combining repeated cytology and BE outperformed models using baseline cytology combined with either test alone in predicting UC and HG events.

Conclusions

In patients with indeterminate urinary cytology and negative cystoscopy, BE provided complementary diagnostic information for the detection of UC events and HG disease. The combination of BE and repeated urinary cytology provided the most accurate risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCytodiagnosisCarcinoma, Transitional CellHumansFemaleProspective StudiesMaleRisk AssessmentAgedCystoscopyMiddle AgedSensitivity and SpecificityPrognosisAged, 80 and over

Stichwörter der Autor:innen

bladder cancercystoscopymethylation testnoninvasive diagnosisurinary cytology

Autor:innen und Institutionen

  • Laboratori i Servei d'Urologia, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Genètica i Tumors Urològics, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Departament de Cirurgia i Especialitats Medicoquirúrgiques, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
  • Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
  • Departament de Bioquímica i Genètica Molecular, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain.

ORCID-Profile: Claudia Mercader

Förderung

  • Nucleix and private grants awarded to LM and AA

Zitieren

APA

Mercader, C., Ingelmo-Torres, M., Roldán, F. L., Figueras, M., Villalba, E., Galve, P., Asiaín, I., Costa, M., Vilaseca, A., Oriola, J., Franco, A., Alcaraz, A., & Mengual, L. (2026). Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck. Cancer Cytopathology, 134(10). https://doi.org/10.1002/cncy.70141

Vancouver

Mercader C, Ingelmo-Torres M, Roldán FL, Figueras M, Villalba E, Galve P, et al. Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck. Cancer Cytopathology. 2026;134(10). doi:10.1002/cncy.70141

BibTeX
@article{Mercader2026,
  author = {Mercader, Claudia and Ingelmo-Torres, Mercedes and Roldán, Fiorella L and Figueras, Marcel and Villalba, Eric and Galve, Pilar and Asiaín, Ignacio and Costa, Meritxell and Vilaseca, Antoni and Oriola, Josep and Franco, Agustín and Alcaraz, Antonio and Mengual, Lourdes},
  title = {Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck},
  journal = {Cancer Cytopathology},
  year = {2026},
  volume = {134},
  number = {10},
  doi = {10.1002/cncy.70141}
}
Kostenlos starten →